Abstract
Immediate reocclusion after successful thrombolysis was angiographically examined in 29 consecutive stroke patients. The reocclusion, which was associated with a high-grade residual stenosis of initially perfused arteries, occurred in four patients. IV abciximab successfully dissolved the thrombus in all four patients. Rapid thrombotic reocclusion after successful thrombolysis is commonly observed in patients after an acute stroke. Administration of abciximab may lead to reperfusion of the reoccluded artery.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Abciximab
-
Acute Disease
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use*
-
Brain Ischemia / diagnostic imaging
-
Brain Ischemia / drug therapy
-
Brain Ischemia / epidemiology*
-
Cerebral Angiography
-
Cerebral Arteries / diagnostic imaging
-
Cerebral Arteries / drug effects*
-
Cerebral Arteries / pathology
-
Constriction, Pathologic
-
Female
-
Fibrinolytic Agents / therapeutic use*
-
Humans
-
Immunoglobulin Fab Fragments / administration & dosage
-
Immunoglobulin Fab Fragments / therapeutic use*
-
Male
-
Middle Aged
-
Pilot Projects
-
Platelet Aggregation Inhibitors / administration & dosage
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
-
Prospective Studies
-
Recurrence
-
Reperfusion
-
Thrombolytic Therapy*
-
Tissue Plasminogen Activator / therapeutic use
-
Treatment Failure
-
Urokinase-Type Plasminogen Activator / therapeutic use
-
Vascular Patency*
Substances
-
Antibodies, Monoclonal
-
Fibrinolytic Agents
-
Immunoglobulin Fab Fragments
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Tissue Plasminogen Activator
-
Urokinase-Type Plasminogen Activator
-
Abciximab